The Pharma Data

JANUARY 10, 2021

Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Supply Trials 52

Metabolite Tales Blog

NOVEMBER 17, 2022

Figure 3: Roquinimex (linomide) Clinical development of both laquinimod and roquinimex was halted due to serious cardiovascular events. Studies in non-clinical species raised no obvious red flags of this clinical outcome. Teva Pharmaceuticals licensed laquinimod from Active Biotech. This was unexpected.

International 52

International Licensing Licensing Treatment 52

The Pharma Data

NOVEMBER 23, 2020

The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. . .

Compliance 52

Compliance Licensing Licensing Clinical Trials 52

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. iii Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events. “We

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

OCTOBER 14, 2020

Live Webcast : accessible from the Company’s website at www.eloxxpharma.com under Events and Presentations or with this link: [link]. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis. Domestic Dial-in Number : (866) 913-8546. International Dial-in Number: (210) 874-7715.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

The Pharma Data

OCTOBER 26, 2020

AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive Staphylococcus aureus ( S. AR-101 is a fully human immunoglobulin M, or IgM, mAb in Phase 2 clinical development targeting Pseudomonas aeruginosa ( P. AR-301 (VAP). aureus) alpha-toxin in VAP patients. AR-101 (HAP).

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

Drug Target Review

OCTOBER 10, 2024

Diseased cells can respond differently to treatment, leading to unforeseen adverse events, including severe toxicity and even death. Addressing unexpected manufacturing challenges, safety concerns, or efficacy issues in later stages can significantly delay clinical development and escalate costs.

Therapies 52

Therapies Immune Response Clinical Trials Disease 52

The Pharma Data

JANUARY 19, 2021

The event will feature a presentation by renowned lymphoma expert Mats Jerkeman, MD, Lund University, who will discuss the current treatment landscape, and unmet medical need for patients with relapsed or refractory Non-Hodgkin’s Lymphoma for whom current treatment options are very limited. LUND, Sweden , Jan. Eastern Time ( 5:30 p.m.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

SugarCone Biotech

JUNE 10, 2024

[link] Immunity is complex and can be dangerous when exploited clinically, as demonstrated by the lethal administration of TNF, or anti-CD40L antibody (Biogen) or CAR-T cells expressing the CD16 Fc-receptor (Unum), among many other examples. These adverse events suggest widespread, uncoordinated and nonspecific immune activation.

Immune Response 88

Immune Response Production Regulations Clinical Trials 88

The Pharma Data

JANUARY 27, 2021

The two-hour event will cover various topics, including an overview of the Company’s board and executive leadership, its commitment to environment, social and governance (ESG) matters, and progress updates on the Company’s critical care programs, manufacturing and distribution approach, and commercial readiness plans. About MultiStem ®.

Clinical Trials 52

Clinical Trials Trials Therapies Production 52

The Pharma Data

JANUARY 19, 2021

(NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company’s business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

Clinical Trials 52

Clinical Trials Trials Clinical Development Pharmaceutical Companies 52

The Pharma Data

APRIL 1, 2021

Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Among the patients who died after receiving Tecartus, one had a fatal CRS event. Serious events associated with CRS included hypotension, fever, hypoxia, acute kidney injury, and tachycardia.

Treatment 52

Treatment Virus Therapies FDA 52

The Pharma Data

DECEMBER 16, 2020

“Since becoming a public company, our clear focus has been on advancing the clinical development of Berubicin. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. . .

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

JANUARY 14, 2021

The incidence of all grade adverse events was similar in the bemarituzumab and placebo arms of the study (100% vs 98.7%, respectively). Corneal events were reported more frequently in the bemarituzumab arm (67.1% Grade 3 and higher adverse events (82.9% vs 74.0%), serious adverse events (31.6%

Trials 52

Trials Treatment Therapies Clinical Trials 52

The Pharma Data

APRIL 27, 2021

IMPORTANT SAFETY INFORMATION: Events of anaphylaxis have been reported. A slightly lower frequency of reactogenicity events was associated with greater age. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

LifeSciVC

JANUARY 16, 2024

Rise of the best-in-class biologics plays: Are you looking to in-license or invest in “de-risked” biology that is already in the clinic? Probably challenging given Cmax-driven adverse event profile, safety requirements, and COGS constraints for an obesity or related indications. Join the club.

Small Molecule 139

Small Molecule Trials Therapies Disease 139

The Pharma Data

JUNE 7, 2022

The frequency of adverse events and the overall safety profile among these patients treated with lebrikizumab were consistent with the induction phase of the trials as well as previous lebrikizumab studies in AD. With these data, Lilly plans to submit a Biologics License Application (BLA) to the U.S. Almirall S.A.’s

Trials 40

Trials Clinical Trials Licensing Licensing 40

The Pharma Data

JANUARY 10, 2021

“We expect 2021 will mark a number of key clinical and commercial milestones. By the end of the year, we expect to have five independent TransCon product candidates in clinical development leveraging TransCon technologies through our algorithm for product innovation. Pipeline Updates. •. ?.

Clinical Trials 40

Clinical Trials Clinical Development Small Molecule Trials 40

The Pharma Data

JANUARY 13, 2021

Fast Track designation facilitates the development and expedites the review of drugs that are intended to treat serious and life-threatening conditions and show the potential to fill an unmet medical need. Brilacidin for UP/UPS was licensed to Alfasigma S.p.A. Source link.

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

The Pharma Data

JANUARY 24, 2021

Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. Food and Drug Administration (“FDA”) approval. PharmaDrug Inc.

FDA 52

FDA Drugs Clinical Development Disease 52

The Pharma Data

JANUARY 27, 2021

We are pleased to be advancing our second therapy into clinical development in our quest to bring transformative medicines to patients who need them,” said Bruce Goldsmith, Ph.D., We are excited to investigate the potential of PBFT02 as a treatment for FTD-GRN as we initiate our clinical development program in the coming months.”.

Therapies 52

Therapies Treatment Clinical Trials FDA 52

The Pharma Data

DECEMBER 14, 2020

The Company anticipates using net proceeds from the offering to fund the continued development of ublituximab and umbralisib, the potential in-license, acquisition, development and commercialization of other pharmaceutical products, and for general corporate purposes. Morgan Securities LLC, Goldman Sachs & Co.

Clinical Trials 40

Clinical Trials Clinical Development Production Trials 40

The Pharma Data

MARCH 4, 2021

No deaths, major adverse cardiovascular events (MACE) or venous thromboembolic events (VTEs) were reported in the study. vice president of immunology development at Lilly. ” Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. . In addition, there were cases of arterial thrombosis.

Trials 52

Trials Therapies Treatment Clinical Trials 52

The Pharma Data

MAY 31, 2022

Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) to treat adults with prurigo nodularis, a chronic inflammatory skin disease that causes extreme itch and skin lesions. The adverse event more commonly observed with Dupixent was conjunctivitis.

FDA 52

FDA Disease Trials FDA Approval 52

The Pharma Data

APRIL 19, 2022

The safety profile of the most common adverse events with Enhertu in DESTINY-Lung01 was consistent with previous clinical trials with no new safety concerns identified. Based on pivotal DESTINY-Lung01 results showing AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a 54.9% The median progression-free survival (PFS) was 8.2

Trials 52

Trials Treatment Therapies FDA 52

The Pharma Data

APRIL 4, 2022

The most common adverse event observed with Dupixent, in Part A and Part B, was injection site reactions. The potential use of Dupixent in EoE is currently under clinical development, and the safety and efficacy have not been fully evaluated by any regulatory authority. In September 2020, the U.S.

FDA 52

FDA Treatment Disease FDA Approval 52

The Pharma Data

JANUARY 3, 2021

The Phase 1/2 clinical trial will primarily investigate the safety and tolerability of INZ-701 and characterize its pharmacokinetic and pharmacodynamic profile, including plasma pyrophosphate (PPi) and other biomarker levels, to establish a recommended dosing regimen for further clinical development. Demetrios Braddock, M.D.,

Clinical Trials 52

Clinical Trials Trials Treatment FDA 52

The Pharma Data

JANUARY 3, 2021

our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; potential off-label sales in the U.S.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

The Pharma Data

MARCH 5, 2021

Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. This vision is what defines us and guides our research, clinical development and partnerships.

Therapies 52

Therapies Trials Clinical Development Treatment 52

The Pharma Data

OCTOBER 29, 2020

In the Phase 2 portion, the most common adverse event was upper respiratory tract infection which occurred in 17.9%, 11.1% No serious adverse events, deaths, thrombotic events or new safety concerns were reported. vice president of immunology development at Lilly. vice president of immunology development at Lilly.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

JANUARY 4, 2021

We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University. Barber’s work will give Kiromic a significant acceleration in the clinical development of its therapy platform and an even more significant advantage over its competitors. “We believe Prof.

Molecular Biology 40

Molecular Biology Therapies Immune Response Science 40

The Pharma Data

FEBRUARY 25, 2021

Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac , its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older. NEW YORK–(BUSINESS WIRE)– Pfizer Inc. NYSE:PFE) today announced that the U.S.

FDA 52

FDA Vaccine Virus Clinical Trials 52

The Pharma Data

JANUARY 13, 2021

.” MindMed Chief Development Officer Rob Barrow said, “Psychedelic therapies offer a once in a lifetime opportunity to revolutionize the delivery of mental healthcare. MindMed Forward-Looking Statements.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

The Pharma Data

DECEMBER 17, 2020

Senior Vice President and Head of Global Clinical Development at Regeneron and lead author of the publication. patients under an Emergency Use Authorization, and we also continue a robust clinical development program.” In the initial 275 patients, rates of adverse events (AEs) were similar among groups.

Hospitals 52

Hospitals Production Clinical Trials Therapies 52

The Pharma Data

JANUARY 18, 2021

The fireside chat will be available for 90+ days following the event at: [link] 5 69. Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

JANUARY 18, 2021

OKYO has been developing the chemerin molecule as a promising anti-inflammatory treatment for dry-eye disease (“DED”) licensed from researchers at On Target Therapeutics LLC. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. LONDON and BOSTON, Jan.

Science 40

Science Virus Treatment Disease 40

The Pharma Data

JULY 22, 2021

“Building on Pfizer’s established leadership position in breast cancer science and CDK 4/6 inhibition, we are excited to work with Arvinas to maximize ARV-471, the first PROTAC for breast cancer with encouraging early clinical data and a potential novel hormonal therapy backbone for HR+ breast cancer,” said Jeff Settleman, Ph.D.,

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52